Core Viewpoint - The article highlights the potential of Minoway Pharmaceutical to become a benchmark enterprise in the field of innovative drugs for consumer healthcare, particularly with its recent achievements in drug development and market positioning [3][6]. Financing and Product Development - Minoway Pharmaceutical recently completed a billion-level Series B financing led by IDG Capital, with existing shareholder Yuanhe Yuandian participating. The funds will be used to accelerate the development of innovative drug pipelines and market promotion of its core product, Rongzhi® [3]. - The company achieved a significant milestone with the approval of its self-developed Deoxycholic Acid Injection (brand name: Rongzhi®) in June this year, making it the first compliant lipolytic injection drug in China. This fills a regulatory gap in the domestic lipolysis treatment market [3][5]. Product Pipeline and Clinical Research - Besides Rongzhi®, Minoway is actively developing new drugs for conditions such as androgenetic alopecia and photoaging, which are expected to enter clinical development by Q4 2025. Additionally, the anti-postpartum depression drug MI078 capsule has completed Phase II clinical trials, showing significant efficacy compared to the placebo group [5][6]. - MI078 is notable as the first anti-postpartum depression drug in China to complete Phase II clinical trials, with the potential to become the first innovative Class I drug with independent intellectual property rights in this field [5][6]. Team and Market Positioning - The core team of Minoway Pharmaceutical is led by a PhD from Tsinghua University and includes members with over 10 years of experience in industrialization in both China and the U.S., providing a solid foundation for technology transfer and product commercialization [6]. - The commercialization of Rongzhi® is being conducted nationwide, targeting a market potential of hundreds of billions in the medical aesthetics sector, positioning the company as a future leader in the innovative drug field for consumer healthcare [6].

近日，迈诺威医药顺利完成亿元级B轮融资，由知名投资机构IDG资本独家领投，老股东元禾原点持续 跟投。据悉，本轮融资将重点用于加速创新药研发管线推进，以及旗下核心产品 "蓉芷®" 溶脂针剂的 市场推广与销售布局，为企业在消费医疗领域药品研发的持续领跑注入强劲动力。 此次融资将充分利用IDG资本的资金支持和资源优势，重点推进两大核心战略，构建"研发+商业化"双 轮驱动体系。据悉，旗下国内首个溶脂针剂"蓉芷®"的商业化已在全国同步进行，剑指百亿级医美消费 市场。有望成为未来消费医疗创新药领域的标杆企业。 IDG资本表示： 作为国内消费医疗创新药研发的新锐力量，迈诺威医药近期迎来重要里程碑：自主研发的DCA去氧胆 酸注射液（品牌名：蓉芷®）已于今年6月成功获批上市，成为中国首个合规溶脂注射药品。这一突破 不仅填补了国内溶脂治疗领域的合规空白，更凭借其精准靶向的技术优势，为广大求美者提供了安全有 效的治疗选择。 | 号:CYHS2400661 | | --- | | 约品名称 | 药品通用名称:去氧胆酸注射液 | | --- | --- | | | 英文名/拉丁名:Deoxycholic Acid Injection ...